GRACEcast ALL Subjects audio and video
ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line (audio)
- Autor: Podcast
- Narrador: Podcast
- Editora: Podcast
- Duração: 0:06:38
- Mais informações
Informações:
Sinopse
Dr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit of chemo or EGFR inhibitor for second line treatment of advanced lung cancer.
